New diabetes pill enters early human testing
NCT ID NCT07234864
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial is testing a new oral drug called ZE63-0302 in 60 adults with type 2 diabetes. The main goal is to check the drug's safety and how the body handles it, not yet whether it works. Participants will take either the drug or a placebo capsule twice a day for a short time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ZE63-0302 (oral capsules)
What this could lead to
If this early trial shows the drug is safe and well-tolerated, it could pave the way for a new oral medication to help control blood sugar in type 2 diabetes.
What could go wrong
This is a very early Phase 1 study with only 60 people, focused on safety and drug levels, not on whether it actually improves diabetes. Many drugs fail at this stage, and side effects are unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Emeritus Research Camberwell
Melbourne, Victoria, 3124, Australia
-
Emeritus Research Sydney
Botany, New South Wales, 2019, Australia
-
Momentum Clinical Research Sunshine
Melbourne, Victoria, 3021, Australia
-
Momentum Clinical Research Taringa
Brisbane, Queensland, 4068, Australia
-
Momentum Dunedin
Dunedin, Otago, 9016, New Zealand
-
Momentum Wellington
Wellington, Wellington Region, 6011, New Zealand
-
PCRN Christchurch
Christchurch, Canterbury, 8013, New Zealand
-
PCRN Rotorua
Rotorua, Bay of Plenty, 3010, New Zealand
-
PCRN Waikato
Hamilton, Waikato Region, 3200, New Zealand
-
The Republican Specialized Scientific and Prectical Medical Center of Endocrinology named after Academician Yo. Kh. Turakulov
Tashkent, Tashkent, 100125, Uzbekistan